Document Detail

Chemotherapy of acute myeloblastic leukaemia with DAM regimen.
MedLine Citation:
PMID:  9621477     Owner:  NLM     Status:  MEDLINE    
32 patients of denovo-ANLL were treated with Doxorubicin, Ara-C and 6-Mercaptopurine (DAM) regimen. Remission induction was instituted with 1-3 cycles of DAM regimen and maintenance was given by 6-MP continuously with intermittent DA (1,5) regimen. In the remission induction, Doxorubicin 30 mg/m2 for 3 days, Ara-C 150 mg/m2 for 5 days and 6-Mp 100 mg/m2 daily was given. Complete remission (CR) was observed in 60% cases. The probability of 2 years disease-free survival of patients with complete remission is 56.73%.
A B Yunus; M A Sayeed; A Barua; J Rahman; M A Rashid
Related Documents :
17071477 - Treatment of acute myeloid leukemia patients aged more than 75 years: results of the e-...
2361737 - Acute non-lymphoblastic leukemia in children: prognostic factors and results of chemoth...
6961037 - Adult acute lymphoblastic leukemia. response to therapy according to presenting feature...
19741727 - High dose ara-c in the treatment of newly diagnosed acute promyelocytic leukemia: long-...
8995557 - Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-...
19463577 - Prognostic factors for recurrence after pulmonary resection of colorectal cancer metast...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Bangladesh Medical Research Council bulletin     Volume:  23     ISSN:  0377-9238     ISO Abbreviation:  Bangladesh Med Res Counc Bull     Publication Date:  1997 Dec 
Date Detail:
Created Date:  1998-07-08     Completed Date:  1998-07-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7607686     Medline TA:  Bangladesh Med Res Counc Bull     Country:  BANGLADESH    
Other Details:
Languages:  eng     Pagination:  82-6     Citation Subset:  IM    
Department of Haematology, Institute of Postgraduate Medicine & Research, Dhaka.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Blood Cell Count / drug effects
Cytarabine / administration & dosage
Disease-Free Survival
Doxorubicin / administration & dosage
Drug Administration Schedule
Leukemia, Myeloid, Acute / drug therapy*
Middle Aged
Remission Induction
Reg. No./Substance:
0/AA1-3 protocol; 147-94-4/Cytarabine; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunofluorescent microscopic findings in glomerulonephritis.
Next Document:  Cut throat injury: a retrospective study of 26 cases.